EurekAlert!

New meta-analysis demonstrates that access to the GeneSight test can significantly improve response and remission rates for patients with depression

SALT LAKE CITY, Sept. 3, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six ...
Nasdaq

Myriad Genetics Study Finds GeneSight Test Reduces Psychiatric Hospitalizations in Major Depressive Disorder Patients

Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...
Seeking Alpha

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of ...
Nasdaq

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of ...
News Medical

GeneSight test better predicts antidepressant outcomes for patients with depression

The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...
EurekAlert!

New post-hoc analysis shows patients whose clinicians had access to GeneSight results for depression treatment are more likely to feel better sooner

SALT LAKE CITY, Oct. 30, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in ...
News Medical

GeneSight test-guided treatment leads to faster remission and response in patients with depression

Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that ...
Business Insider

Why Seniors Must Speak Up About Mental Health: Patient and Clinician Share Insights on YourUpdateTV

September Healthy Aging Month: How Genetic Testing May Help Clinicians Find Mental Health Medications for Seniors The GeneSight test helps inform clinicians about how they may respond to certain ...